Prevention therapy in patients with the severу hepatorenal syndrome

Korean Journal of Transplantation, 2022

Full text Open access: Gold Metadata (CSL-JSON)
DOI 10.4285/atw2022.f-3538
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Background: Hepatorenal syndrome (HRS) plays an important role in patients with liver cirrhosis before liver transplantation. To determine the dynamics of the severity of the condition and prediction of the estimated risk of mortality (ERM) patients with HRS using cellular mediators.